背景:有最少的流行病学数据比较了英国与其他国家的肠道脑相互作用(DGBI)疾病的负担。我们比较了英国DGBI的患病率与参加罗马基金会全球流行病学研究(RFGES)在线的其他国家。
方法:来自26个国家的参与者在线完成了RFGES调查,包括罗马IV诊断问卷和深入的补充问卷,其中包含有关饮食习惯的问题。将英国的社会人口统计学和患病率数据与其他25个国家进行了比较。
结果:与其他25个国家相比,英国参与者中至少有一个DGBI的参与者比例较低(37.6%95%CI35.5%-39.7%vs.41.2%;95%CI40.8%-41.6%,p=0.001)。英国流行22个罗马IVDGBI中的14个,包括肠易激综合征(4.3%)和功能性消化不良(6.8%),与其他国家相似。大便失禁,阿片类药物引起的便秘,慢性恶心和呕吐,大麻素剧吐(p<0.05)在英国更为普遍。周期性呕吐,功能性便秘,未指明的功能性肠病,在其他25个国家/地区,福氏直肠病(p<0.05)更为普遍。英国人口的饮食包括较高的肉类和牛奶消费量(p<0.001),减少大米的消费,水果,鸡蛋,豆腐,意大利面,蔬菜/豆类,和鱼(p<0.001)。
结论:在英国和世界其他地区,DGBI的患病率和负担一直很高。阿片类药物处方,文化,饮食,和生活方式因素可能导致英国和其他国家某些DGBI患病率的差异。
There are minimal epidemiological data comparing the burden of disorders of gut brain interaction (DGBI) in the UK with other countries. We compared the prevalence of DGBI in the UK with other countries that participated in the Rome Foundation Global Epidemiology Study (RFGES) online.
Participants from 26 countries completed the RFGES survey online including the Rome IV diagnostic questionnaire and an in-depth supplemental questionnaire with questions about dietary habits. UK sociodemographic and prevalence data were compared with the other 25 countries pooled together.
The proportion of participants with at least one DGBI was lower in UK participants compared with in the other 25 countries (37.6% 95% CI 35.5%-39.7% vs. 41.2%; 95% CI 40.8%-41.6%, p = 0.001). The UK prevalence of 14 of 22 Rome IV DGBI, including irritable bowel syndrome (4.3%) and functional dyspepsia (6.8%), was similar to the other countries. Fecal incontinence, opioid-induced constipation, chronic nausea and vomiting, and cannabinoid hyperemesis (p < 0.05) were more prevalent in the UK. Cyclic vomiting, functional constipation, unspecified functional bowel disorder, and proctalgia fugax (p < 0.05) were more prevalent in the other 25 countries. Diet in the UK population consisted of higher consumption of meat and milk (p < 0.001), and lower consumption of rice, fruit, eggs, tofu, pasta, vegetables/legumes, and fish (p < 0.001).
The prevalence and burden of DGBI is consistently high in the UK and in the rest of the world. Opioid prescribing, cultural, dietary, and lifestyle factors may contribute to differences in the prevalence of some DGBI between the UK and other countries.